Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GSKNYSE:RDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSKGSK$38.74+0.6%$37.22$31.72▼$45.93$80.19B0.584.43 million shs3.22 million shsRDYDr. Reddy's Laboratories$13.20-0.6%$13.48$12.50▼$16.89$11.01B0.481.31 million shs2.05 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSKGSK0.00%-1.23%+3.07%+15.13%-9.63%RDYDr. Reddy's Laboratories0.00%-3.86%+3.37%-16.01%-10.05%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGSKGSK2.8567 of 5 stars2.35.02.50.03.00.01.3RDYDr. Reddy's Laboratories3.3958 of 5 stars3.34.01.70.02.90.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGSKGSK 2.60Moderate Buy$43.2511.64% UpsideRDYDr. Reddy's Laboratories 2.50Moderate Buy$17.0028.84% UpsideCurrent Analyst Ratings BreakdownLatest GSK and RDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/12/2025GSKGSKMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGSKGSK$31.38B2.56$6.13 per share6.32$8.07 per share4.80RDYDr. Reddy's Laboratories$311.31B0.04$1.00 per share13.25$4.50 per share2.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGSKGSK$3.29B$1.5924.378.331.128.13%48.59%11.11%5/7/2025 (Estimated)RDYDr. Reddy's Laboratories$668M$0.6321.0116.09N/A17.25%17.87%12.32%5/6/2025 (Estimated)Latest GSK and RDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/5/2025Q4 2024GSKGSK$0.44$0.59+$0.15$0.26$7.75 billionN/A1/23/2025Q3 2025RDYDr. Reddy's Laboratories$0.19$0.20+$0.01$0.20$975.71 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGSKGSK$1.574.05%-17.33%98.74%N/ARDYDr. Reddy's Laboratories$0.080.61%N/A12.70%N/ALatest GSK and RDY DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/5/2025GSKGSKquarterly$0.39324.2%2/21/20252/21/20254/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGSKGSK1.120.780.52RDYDr. Reddy's Laboratories0.021.921.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGSKGSK15.74%RDYDr. Reddy's Laboratories3.85%Insider OwnershipCompanyInsider OwnershipGSKGSK10.00%RDYDr. Reddy's Laboratories2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGSKGSK90,1002.07 billion1.87 billionOptionableRDYDr. Reddy's Laboratories24,800834.76 million818.05 millionOptionableGSK and RDY HeadlinesRecent News About These CompaniesHighTower Advisors LLC Takes Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)March 31 at 3:11 AM | marketbeat.comSegall Bryant & Hamill LLC Makes New Investment in Dr. Reddy's Laboratories Limited (NYSE:RDY)March 30 at 4:24 AM | marketbeat.comBio-Thera And Dr. Reddy's Partner To Launch Stelara And Simponi Biosimilars In Southeast AsiaMarch 29 at 12:28 PM | nasdaq.comBio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast AsiaMarch 27, 2025 | prnewswire.comDr. Reddy's Laboratories Limited (NYSE:RDY) Holdings Boosted by Natixis Advisors LLCMarch 27, 2025 | marketbeat.comDr. Reddy's Laboratories (NYSE:RDY) Shares Gap Down - Here's What HappenedMarch 26, 2025 | marketbeat.comGQG Partners LLC Purchases 1,571,808 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)March 26, 2025 | marketbeat.comSummit Global Investments Raises Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)March 24, 2025 | marketbeat.comCorient Private Wealth LLC Grows Stock Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)March 24, 2025 | marketbeat.comDr. Reddy's Laboratories Limited (NYSE:RDY) Shares Purchased by Bank of New York Mellon CorpMarch 24, 2025 | marketbeat.comAikya Investment Management Ltd Boosts Stock Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)March 22, 2025 | marketbeat.comEquities Analysts Issue Forecasts for RDY Q4 EarningsMarch 21, 2025 | marketbeat.comParallel Advisors LLC Has $1.15 Million Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)March 21, 2025 | marketbeat.comZacks Research Has Positive Estimate for RDY Q4 EarningsMarch 21, 2025 | americanbankingnews.comDr. Reddy's Laboratories Limited (NYSE:RDY) Shares Purchased by Victory Capital Management Inc.March 20, 2025 | marketbeat.comFDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for ReviewMarch 19, 2025 | zacks.comPDS Planning Inc Boosts Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)March 19, 2025 | marketbeat.comPNC Financial Services Group Inc. Increases Stock Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)March 19, 2025 | marketbeat.comDr. Reddy's Laboratories (NYSE:RDY) Shares Gap Up - Here's What HappenedMarch 18, 2025 | marketbeat.comAlvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®March 18, 2025 | markets.businessinsider.comAlvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®March 18, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGSK and RDY Company DescriptionsGSK NYSE:GSK$38.74 +0.22 (+0.58%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$38.60 -0.15 (-0.38%) As of 03/28/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Dr. Reddy's Laboratories NYSE:RDY$13.20 -0.08 (-0.57%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$13.19 -0.01 (-0.04%) As of 03/28/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
